CL2016001096A1 - Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico. - Google Patents
Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico.Info
- Publication number
- CL2016001096A1 CL2016001096A1 CL2016001096A CL2016001096A CL2016001096A1 CL 2016001096 A1 CL2016001096 A1 CL 2016001096A1 CL 2016001096 A CL2016001096 A CL 2016001096A CL 2016001096 A CL2016001096 A CL 2016001096A CL 2016001096 A1 CL2016001096 A1 CL 2016001096A1
- Authority
- CL
- Chile
- Prior art keywords
- dihydro
- benzoxazol
- inden
- dioxo
- oxo
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- JDARDSVOVYVQST-MRXNPFEDSA-N 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxylic acid Chemical compound C1CC(C(=CC=C2)C(F)(F)F)=C2[C@@H]1N(C1=O)C(=O)C(C(O)=O)=CN1C1=CC=C2N(C)C(=O)OC2=C1 JDARDSVOVYVQST-MRXNPFEDSA-N 0.000 title 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001096A1 true CL2016001096A1 (es) | 2016-12-23 |
Family
ID=49552231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001096A CL2016001096A1 (es) | 2013-11-08 | 2016-05-06 | Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico. |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| CA3061444A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| US20250302837A1 (en) * | 2022-04-05 | 2025-10-02 | Socpra Sciences Santé Et Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001295952A1 (en) * | 2000-10-19 | 2002-04-29 | Nippon Kayaku Kabushiki Kaisha | Novel remedies or preventives for angiostenosis |
| AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
| CN104168779A (zh) * | 2012-03-05 | 2014-11-26 | 格拉图克技术私人有限公司 | 膳食补充剂 |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| HK1224288A1 (zh) * | 2013-11-08 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
-
2014
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active Active
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de not_active Ceased
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-06 PH PH12016500853A patent/PH12016500853B1/en unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
-
2017
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600185A (es) | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| CL2018001560A1 (es) | Moléculas de anticuerpos para pd-1 y sus usos | |
| CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
| CL2017000888A1 (es) | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas | |
| CL2015002279A1 (es) | Amidas heterocíclicas como inhibidores de cinasas | |
| MX384909B (es) | Un anticuerpo anti-tau para usarse al tratar una tauopatía. | |
| EP3317842A4 (en) | GAMIFICATION SYSTEMS AND METHOD FOR IMPROVED HEALTH CARE RESULTS | |
| FR3025902B1 (fr) | Souris vibrante multi-dimensions | |
| CL2017000944A1 (es) | Compuesto heterocíclico | |
| CL2016001096A1 (es) | Sales de acido 1-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-6-il)-2,4-dioxo-3-[(1r)-4-(trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2, 3, 4 - tetrahidropirimidin-5-carboxilico. | |
| BR112017008154A2 (pt) | construção de gerenciamento de luz | |
| CL2015002181A1 (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod. | |
| HUE042175T2 (hu) | Olaj szénszál prekurzor akrilszálhoz, olaj kompozíció szénszál prekurzor akrilszálhoz, olaj kezelõfolyadék szénszál prekurzor akrilszálhoz, és szénszál prekurzor akrilszál nyaláb | |
| CL2016000984A1 (es) | Sistema y método para la implementación de consultas de búsqueda multi-facetadas | |
| MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| BR112017007509A2 (pt) | Processo para a preparação de 1-(3,5-dicloro-4- fluoro-fenil)-2,2,2-trifluoro-etanona | |
| CL2015003668A1 (es) | Método de tratamiento de trastornos neurodegenerativos. | |
| BR112016011554A2 (pt) | Uso de brometo para minimizar ou prevenir a indução de inanição relacionada ao estresse ou inanição relacionada à ansiedade em um animal durante, ou em conclusão de, uma prática de comercialização ou gestão | |
| EA201691894A1 (ru) | Лечение эпилептических расстройств у представителей кошачьих | |
| Chiarella et al. | Computational methods for derivatives with early exercise features | |
| TH178678A (th) | เกลือแบบใหม่ของ 1-(3-เมธิล-2-ออกโซ-2,3-ไดไฮโดร-1,3-เบนซอกซาโซล-6-อิล)-2,4- ไดออกโซ-3-[(1r)-4-(ไตรฟลูออโรเมธิล)-2,3-ไดไฮโดร-1h-อินดิน-1-อิล]-1,2,3,4- เตตระไฮโดรไพริมิดีน-5-คาร์บอกซิลิกแอซิดและการใช้เกลือดังกล่าว | |
| CL2013001170A1 (es) | Un metodo para proveer un servicio de administracion de membresia multinivel susucrita en linea y realimenta la ganancia de acuerdo con una regla predeterminada cuando se vende un producto o servcio. | |
| UA107534U (uk) | Застосування вінборону для потенціювання аналгетичного ефекту ібупрофену | |
| TH1601006736A (th) | กระบวนการสำหรับการได้รับมาของเพอร์ลินโดลอีแนนทิโอเมอร์ที่แอคทีฟเชิงออพติคอลและเกลือของสิ่งเหล่านี้ |